Addex Therapeutics (ADXN) Interest Expenses (2019 - 2026)

Addex Therapeutics has reported Interest Expenses for 8 years, with the latest figure at -$812.2 million in Q1 2026.

• Quarterly Interest Expenses fell 33.25% year-over-year to -$812.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$812.2 million (down 14.78% YoY) and the FY2025 annual result came in at $18751.7, up 365.09% from the prior year.
• Interest Expenses retreated to -$812.2 million in Q1 2026 per ADXN's latest filing, from -$1021.3 in the prior quarter.
• Over five years, Interest Expenses peaked at $14.9 billion in Q4 2023 and troughed at -$8.9 billion in Q3 2024.
• A 5-year average of $141.0 million and a median of -$6825.0 in 2022 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2023 and 2024: Interest Expenses jumped 4316091.08% in 2023, then sank 71745006.97% in 2024.
• Over 5 years, Interest Expenses stood at $346113.9 in 2022, then surged by 4316091.08% to $14.9 billion in 2023, then plunged by 40.91% to $8.8 billion in 2024, then tumbled by 100.0% to -$1021.3 in 2025, then slumped by 79520470.68% to -$812.2 million in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered -$812.2 million, -$1021.3, and -$7039.6 for Q1 2026, Q3 2025, and Q2 2025 respectively.